AKT1 and neoplasm: The FAKTION authors reported a significant PFS and overall survival (OS) benefit favouring the novel combination; however, subgroup analysis showed that this benefit was primarily in patients considered to have PIK3/AKT/PTEN pathway alteration, with no significant benefit seen in non-altered tumours (17).